Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Multiple Myeloma 107Lymphoma 48Lymphoma, Non-Hodgkin 44Hodgkin Disease 44Leukemia, Myeloid, Acute 41Myelodysplastic Syndromes 40Leukemia 34Precursor Cell Lymphoblastic Leukemia-Lymphoma 33Leukemia, Lymphocytic, Chronic, B-Cell 28Lymphoma, Mantle-Cell 26Neoplasms, Plasma Cell 25Lymphoma, Large B-Cell, Diffuse 24Lymphoma, Follicular 24Lymphoma, B-Cell, Marginal Zone 18Burkitt Lymphoma 18Leukemia, Myelogenous, Chronic, BCR-ABL Positive 17Myeloproliferative Disorders 16Recurrence 14Immunoglobulin Light-chain Amyloidosis 14Congenital Abnormalities 13Primary Myelofibrosis 12Lymphoma, Large-Cell, Immunoblastic 12Leukemia, Myeloid, Accelerated Phase 12Hematologic Neoplasms 12Waldenstrom Macroglobulinemia 10Lymphoma, T-Cell, Cutaneous 10Leukemia, Myelomonocytic, Juvenile 10Leukemia, Myelomonocytic, Chronic 10Leukemia, Myeloid, Chronic-Phase 10Dendritic Cell Sarcoma, Interdigitating 10

Interventions

Paclitaxel 22Carboplatin 18liposomal doxorubicin 14Bevacizumab 9Topotecan 8Docetaxel 8Gemcitabine 7Cisplatin 7rucaparib 6pembrolizumab 6mirvetuximab soravtansine 5Cyclophosphamide 5Taxes 4Albumin-Bound Paclitaxel 4sargramostim 3ixabepilone 3Cytoreduction Surgical Procedures 3CCV-AV protocol 3130-nm albumin-bound paclitaxel 3taxane 2talazoparib 2pazopanib 2olaparib 2fludarabine phosphate 2fludarabine 2denileukin diftitox 2cediranib 2catumaxomab 2belinostat 2avelumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Ovarian Epithelial × Melphalan × Clear all
NCT00583622 2013-05-21

Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients

M.D. Anderson Cancer Center

Phase 2 Terminated
13 enrolled 5 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡